Security record · archived quarter
DMRA
Damora Therapeutics, Inc. · Healthcare · Biotechnology
3Tracked holders
+1Δ holders
35.44KShares held
$131,837Reported value
+1New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 50 | +22 | 25.23M | $652.63M | +26 | −4 |
| Q1 2026 | 29 | +19 | 19.88M | $515.11M | +19 | — |
| Q4 2025 | 10 | +3 | 470.62K | $50.80M | +5 | −2 |
| Q3 2025 | 3 | +1 | 35.44K | $131,837 | +1 | — |
| Q2 2025 | 2 | 0 | 14.64K | $49,936 | — | — |
| Q1 2025 | 1 | 0 | 15.34K | $47,566 | — | — |
| Q4 2024 | 1 | 0 | 15.04K | $69,955 | — | — |
| Q3 2024 | 1 | +1 | 21.38K | $259,791 | +1 | — |
Who holds it · Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Two Sigma Investments ✦ | 20.30K | New | $75,501 | 0.0% | New | 1 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 15.04K | +3.4% | $55,964 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 100 | 0.0% | $372 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $75,501 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 64 holders, 53.64M shares, $1.39B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2025 ·
Methodology ·
Get this via the API